My HPRA: Register

Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i) - Important Safety Information from marketing authorisation holders of products containing SGLT2 inhibitors as approved by the HPRA

Notice type: 3rd Party Publications

Date: 22/01/2019

Problem Or Issue:
Important Safety Information communication from marketing authorisation holders of products containing SGLT2 inhibitors on the risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i).

Important Safety Information - Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i)

« Back